Business
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
-- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion -- SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today
About this update from Omeros Corporation
[{"type":"text","content":"\n-- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion --\n\n SEATTLE--(BUSINESS WIRE)--\nOmeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% reduces use of the opioid fentanyl during cataract surgery while also reducing surgical pain were published today in the peer-reviewed journal Clinical Ophthalmology. The article, The Effect of Phenylephrine/Ketorolac Intracameral Solution 1%/0.3% on Pain and Opioid Use During Cataract Surgery, is authored by the study investigator Eric D. Donnenfeld, M.D., Clinical Professor of Ophthalmology at New York University and recent past president of the American Society of Cataract and Refractive Surgery. OMIDRIA is approved by FDA for prevention of miosis (pupil constriction) and for reduction in postoperative pain for adults and pediatric patients undergoing cataract or lens replacement surgery.\n\n\nThe study objectives were to evaluate the effect of OMIDRIA compared to epinephrine on perioperative fentanyl use and pain in patients undergoing cataract surgery. Sixty patients were prospectively assigned to have either OMIDRIA (41 patients) or epinephrine (19 patients) added to the irrigation solution used during surgery. Patients in the OMIDRIA group were 6.7 times more likely not to require fentanyl, with 9.8 percent of OMIDRIA patients requiring fentanyl versus 42.1 percent of epinephrine patients (P = 0.006). In addition, mean visual analog scale (VAS of 0-10) pain scores were significantly (48.9 percent) lower in the OMIDRIA group than in the epinephrine group (2.3 vs 4.5; P \n\n“Our study found that OMIDRIA cut intraoperative pain scores in half while markedly reducing the need for fentanyl during cataract surgery,” said Dr. Donnenfeld. “Fentanyl is a mainstay of anesthesia during cataract surgery. The ability of OMIDRIA to reduce pain and the need for fentanyl is a welcome advance for cataract surgery patients, a population already at risk for increased exposure to and dependence on opioids. OMIDRIA is the only drug used during cataract surgery that has demonstrated these important benefits.”\n\n\nDeaths in the U.S. from synthetic opioids, especially fentanyl, have increased more than 10-fold bet...